P2.14-63 Cost Analysis of the Management of CNS Metastases in Patients with Advanced ALK+ NSCLC: Alectinib vs Crizotinib

Autor:	N. Ortega, Itziar Oyagüez, B. Massuti, Rocío Gordo, M. Lázaro, L. Ruiz De Alda, Dolores Isla
Rok vydání:	2019
Předmět:	Pulmonary and Respiratory Medicine Oncology Alectinib medicine.medical_specialty Crizotinib business.industry Internal medicine medicine Cost analysis In patient business medicine.drug
Zdroj:	Journal of Thoracic Oncology. 14:S856
ISSN:	1556-0864
DOI:	10.1016/j.jtho.2019.08.1848
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::cf59129301b37cb8e0188a6c1a688005 https://doi.org/10.1016/j.jtho.2019.08.1848 Zobrazit plný text záznamu